NCT00939458已完成1 期
A Randomized, Open Label, Single Dose, Crossover, Bioequivalence Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects,Under Fed Conditions
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
- 主要终点
- Bioequivalence
研究概览
简要总结
-
Objective:
-
To assess the bioequivalence of Lamotrigine 2 x 25 mg IR tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg tablets of Glaxo-SmithKline, USA, in healthy human adult subjects, under fed conditions.
-
Study Design:
-
A randomized, open label, two treatment, two period, two sequence, single dose, crossover study, under fed conditions.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Healthy adult subjects of either sex between 18-55 years of age (inclusive), having a body mass index (BMI) between 18 and 27 kg/m2
- •Subjects who have no evidence of underlying disease during screening and whose physical examination is performed within 21 days prior to commencement of the study.
- •Subjects whose screening laboratory values are within normal limits or values outside normal limits considered by the physician/Principal Investigator to be of no clinical significance.
- •Informed consent given in written form according to section 11.3 of the protocol.
- •Female Subjects:
- •of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
- •postmenopausal for at least 1 year.
- •surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
排除标准
- •Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
- •Alcohol dependence, alcohol abuse or drug abuse within past one year.
- •Moderate to heavy smoking (> 10 cigarettes/day) or consumption of tobacco products.
- •History of difficulty in swallowing tablet.
- •Clinically significant illness within 4 weeks before the start of the study
- •Asthma, urticaria or other allergic type reactions after taking any medication.
- •Positive urine drug screening, HIV, Hepatitis B & C tests.
- •Any history of hypersensitivity to Lamotrigine.
- •Existence of any surgical or medical condition, which, in the judgment of clinical investigator might interfere with the pharmacokinetics of the drug or likely to compromise the safety of the subject.
- •Inability to communicate or co-operate with the investigator due to language problem, attitude, poor mental development/impaired cerebral function.
结局指标
主要结局
Bioequivalence
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fed ConditionHealthyNCT01131975Dr. Reddy's Laboratories Limited26
已完成
1 期
Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting ConditionHealthyNCT01131949Dr. Reddy's Laboratories Limited26
已完成
1 期
Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting ConditionsHealthyNCT00834561Teva Pharmaceuticals USA32
已完成
4 期
Lamotrigine BioequivalenceEpilepsyNCT01995825University of Maryland, Baltimore35
已完成
1 期
Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting ConditionsFastingNCT06199791Desitin Arzneimittel GmbH24